Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
  • 74 views
  • 24 May, 2021
  • 79 locations
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)

transgender women (TGW) who have sex with men and who are at high risk of HIV-1 infection with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization

  • 0 views
  • 03 Jun, 2021
  • 14 locations
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.

  • 0 views
  • 22 Apr, 2021
  • 13 locations
DORA: The Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV in South Africa

This is a pilot study investigating the safety of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in women of reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy on metabolic and neuropsychiatric outcomes.

  • 0 views
  • 26 Jan, 2021
  • 2 locations
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

The primary purpose of the study is to evaluate the efficacy of rilpivirine (RPV)-based regimen in human immunodeficiency virus type 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive participants, as determined by the percentage of virologic responders defined as having HIV-1 ribonucleic acid (RNA) less than 400 copies/ milliliter (mL) at Week …

  • 25 views
  • 16 Jun, 2021
  • 7 locations
Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients

Combined antiretroviral therapy (ART) efficiently suppresses viral replication and markedly decreases mortality among patients with HIV-1 infection/AIDS. While the advanced AIDS patients with

  • 0 views
  • 18 Feb, 2021
  • 1 location
Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Healthy American and African Adults

This is a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetics of two broadly neutralizing monoclonal human antibodies (bNAbs), 3BNC117-LS-J, which targets the CD4 binding site on HIV-1 envelope protein, and 10-1074-LS-J which targets the V3 loop of HIV-1 envelope protein. The hypothesis is that the two antibodies …

  • 78 views
  • 27 Jan, 2021
  • 8 locations
Randomized Double-blind Efficacy and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-na ve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

treatment-nave participants with human immunodeficiency virus type-1 (HIV-1) infection. The primary hypothesis is that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF

  • 4 views
  • 13 Jun, 2021
  • 67 locations
Kenya HIV Self-Testing in PrEP Delivery

In a three-arm, randomized trial, the investigators will test the use of HIV-1 self-testing to decrease the frequency and burden of clinic visits for PrEP while resulting in equivalent PrEP adherence and HIV testing.

  • 1 views
  • 24 Jan, 2021
  • 1 location
ANRS 12372 MODERATO Study

MODERATO is a phase III, open-label, randomized, multicenter, non-inferiority trial conducted in West and Central Africa (Cameroon, Cte d'Ivoire, Burkina Faso). HIV-1 infected adults receiving first line ART with TDF+XTC+EFV virologically suppressed will be recruited and followed during 100 weeks. The objective is to assess the non-inferiority of a strategy …

  • 0 views
  • 28 Jan, 2021
  • 5 locations